2016 International Congress Archives - Page 13 of 207

12:00pm-1:30pm: Correlation between Parkinson’s disease and malignant tumors

E. Binaghi, M.M. Mascia, P. Solla, M. Meloni, R. Farris, D. Ciaccio, G. Orofino, F. Marrosu, A. Cannas (Cagliari, Italy)

Parkinson's disease: Clinical trials, pharmacology and treatment · Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm: Coupling between visual information and body sway in people with Parkinson’s disease

C.F. Cruz, L.A.O.A. Nóbrega, E. Okamoto, M.E.P. Piemonte, J.A. Barela (São Paulo, Brazil)

Other · Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm: Creatine for patients with Parkinson’s disease: A meta-analysis

A. Attia, H. Ahmed, M. Morsi, K. Awad, M. Elnenny, E. Ghanem, A. Negida (Cairo, Egypt)

Parkinson's disease: Clinical trials, pharmacology and treatment · Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm: Creativity related to dopaminergic treatment. A multicenter study

P.J. Garcia Ruiz, J.C. Martinez Castrillo, L. Vela (Madrid, Spain)

Parkinson's disease: Clinical trials, pharmacology and treatment · Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm: Creutzfeldt-Jakob disease presenting predominantly with movement disorder: A case report

A.A. Sann, M.M. Zaw, T.L. Choie (Yangon, Myanmar)

Other · Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm: Critical path for Parkinson’s, I: Data sharing and regulatory science in catalyzing innovation for Parkinson’s disease

K. Romero, D. Burn, M. Hu, A. Yarnell, C. Williams Gray, K. Marek, D. Grosset, M. Sutherland, M. Isaac, A. Bhattaram, V. Sinha, M.F. Gordon, P. Muglia, L. Slicker, W. Hirst, M. Facheris, J. Posener, M. Bani, B. Corrigan, R. Schindler, K. Tsai, T. Nicholas, J. Cedarbaum, J. Gallagher, S. Ford, E. Avilex, V. Kern, S. Arneric, D. Stephenson, A. Roach (Tucson, AZ, USA)

Parkinson's disease: Clinical trials, pharmacology and treatment · Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm: CSF level of chromogranin A in amyotrophic lateral sclerosis

M. Kaiserova, P. Otruba, K. Mensikova, Z. Grambalova, H. Prikrylova Vranova, J. Mares, D. Stejskal, P. Kanovsky (Olomouc, Czech Republic)

Other · Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm: Curcumin supplementation improves motor dysfunction in lipopolysaccharide induced Parkinon’s disease model: Possible biochemical, neurochemical and immunohistochemical alterations in rats

N. Sharma, B. Nehru (Chandigarh, India)

Neuropharmacology · Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm: Day case initiation of subcutaneous apomorphine in people with Parkinson’s disease: A retrospective analysis from a UK teaching hospital

K. Nalamada, J. Cosgrove, P. Duggan-Carter, S. Jamieson, J. Alty (Leeds, United Kingdom)

Parkinson's disease: Clinical trials, pharmacology and treatment · Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm: DBS outcomes in a mixed cohort of dystonia: A single center experience

O. Saeed, I. Haq, S.B. Tatter, A.W. Laxton, T. Wilson, M. Siddiqui (Winston Salem, NC, USA)

Dystonia · Exhibit Hall located in Hall B, Level 2